Sera Joins $10.4M Federal Push to End Childbirth Guesswork

SALT LAKE CITY, UT – June 24, 2026 – For fifty years, the primary tool used to monitor a baby’s well-being during labor has remained largely unchanged, relying on subjective interpretations of squiggly lines on a paper strip. This technological stagnation in the delivery room contributes to a troubling reality: the United States has one of the highest maternal mortality rates among developed nations. Now, a high-stakes federal initiative is betting it can change that.

The Advanced Research Projects Agency for Health (ARPA-H), the government’s high-risk, high-reward medical research incubator, has awarded up to $10.4 million to a multi-institutional team tasked with a singular goal: to develop a rapid, point-of-care blood test that can objectively detect fetal distress. The collaboration brings together researchers from the University of California San Diego, sensor-tech firm Allegro MicroSystems, and publicly traded diagnostics company Sera Prognostics (Nasdaq: SERA). Their mission is to replace clinical guesswork with data-driven precision, potentially transforming the safety and economics of childbirth.

The Fifty-Year Stagnation in Labor Monitoring

The current standard of care, electronic fetal monitoring (EFM), uses cardiotocography to track a baby’s heart rate against the mother’s contractions. While intended to spot fetal hypoxia—a dangerous lack of oxygen—the technology is notoriously imprecise.

"The fundamental problem with current monitoring is its high false-positive rate," explained a maternal-fetal medicine specialist not involved with the project. "A non-reassuring heart rate pattern can be caused by many things other than hypoxia. This leads to a cascade of interventions, most notably a sharp increase in emergency Cesarean sections that are often, in hindsight, unnecessary."

These unnecessary surgeries carry significant risks for mothers, including infection, hemorrhage, and longer recovery times, while also driving up healthcare costs. The MOCS (Making Obstetrics Care Smart) program, under which this new award was granted, was created by ARPA-H specifically to break this cycle. The agency aims to fund disruptive solutions that cannot be readily achieved through traditional research channels, targeting problems too complex or risky for the private sector to tackle alone. The goal is to move from subjective pattern recognition to objective, biochemical evidence.

A New Blueprint: Biomarkers, Biosensors, and Big Data

The project funded by ARPA-H proposes a radical departure from the status quo. Instead of listening from the outside, the team plans to look inside, analyzing a small maternal blood sample for protein biomarkers that signal placental dysfunction or fetal stress. The vision is a handheld device that can deliver a clear, quantitative risk score for fetal hypoxia within minutes.

This ambitious goal requires a unique convergence of expertise, a model for the kind of public-private partnership ARPA-H seeks to foster.
* UC San Diego: Acting as the academic hub, researchers co-led by engineer Drew Hall and physician-scientist Dr. Louise Laurent will perform the foundational work of identifying the specific protein biomarkers that reliably predict fetal hypoxia. Their work bridges the gap between deep medical science and practical engineering.
* Allegro MicroSystems: A leader in magnetic sensing, Allegro will provide the core hardware technology. The company plans to adapt its proprietary giant magnetoresistive (GMR) semiconductor technology, typically used in automotive and industrial applications, for high-speed biological sensing. This is the key to miniaturizing the test into a rapid, point-of-care platform.
* Sera Prognostics: Known as "The Pregnancy Company®," Sera brings crucial experience in the discovery, validation, and commercialization of pregnancy-related biomarkers. They will lend their expertise to help validate the biomarker signatures identified by UC San Diego, ensuring they are clinically meaningful and robust.

"This work reflects a broader shift in maternal health from reacting to complications to proactively identifying risk and enabling earlier informed decision-making," said Zhenya Lindgardt, President and CEO of Sera Prognostics, in the company’s announcement. This proactive approach is the core of the project's disruptive potential.

Sera’s Strategic Bet on Precision Pregnancy

For Sera Prognostics, this collaboration is more than just a research project; it's a strategic expansion that builds directly on its core business. The company’s flagship product, the PreTRM® Test, is currently the only commercially available blood test to predict a woman's individualized risk of preterm birth early in pregnancy (at 19-20 weeks).

The value of this biomarker-driven approach was recently validated by the landmark PRIME study. The results, announced earlier this year, showed that using the PreTRM® test to identify high-risk women and provide targeted interventions led to a 56% reduction in births before 32 weeks and a 20% drop in both NICU admissions and overall newborn morbidity. For a company whose revenues currently depend almost entirely on this single test, the study provided powerful clinical and economic validation.

The ARPA-H project allows Sera to leverage its proven expertise in proteomics and apply it to a different, but equally critical, challenge in pregnancy: intrapartum complications. Success would open up an entirely new market segment for the company within the booming prenatal diagnostics space, a market projected to grow from $9.2 billion in 2024 to over $32 billion by 2035. This move diversifies Sera's pipeline and positions it as a leader in "precision pregnancy," offering data-driven insights from the second trimester through delivery.

The Road from Lab to Labor Room

While the potential is immense, the path forward is challenging. Developing a clinically reliable biomarker test, integrating it into a low-cost, easy-to-use device, and securing regulatory approval is a multi-year endeavor fraught with scientific and commercial hurdles. This is precisely why ARPA-H's high-risk funding model is so critical.

The MOCS program mandates that any developed technology be tested across diverse clinical settings, including rural hospitals and birthing centers, not just major urban academic hospitals. This requirement is designed to ensure that the final product is accessible and equitable, addressing health disparities that are rampant in U.S. maternal care.

If successful, the impact could be profound. An objective test for fetal hypoxia could empower clinicians with the confidence to avoid unnecessary C-sections, while also providing an earlier, more definitive warning when intervention is truly needed. This would not only improve outcomes for mothers and babies but also significantly reduce the estimated $25 billion annual cost associated with preterm birth and its complications in the United States. The $10.4 million federal investment is a calculated bet that a few drops of blood can deliver the clarity needed to make childbirth safer for everyone.